title: [Predictive value of pre-treatment hypoalbuminemia in prognosis of resected colorectal cancer].
abstract: BACKGROUND
  Albuminemia is part of the antitumoral systemic inflammatory response. We therefore analyzed its possible value in establishing the preoperative prognosis of colorectal carcinoma (CRC).
  
  
  METHODS
  We conducted a retrospective, observational study of a series of consecutive patients who underwent CRC resection. Univariate and multivariate analyses of survival curves were performed in patients with and without pre-treatment hypoalbuminemia (<3.5g/dl), both in the overall group of patients and in the subgroup of those with pTNM stage ii tumors. In addition, we compared the 5-year tumor-related mortality in patients with and without hypoalbuminemia.
  
  
  RESULTS
  A total of 207 patients were reviewed (median follow-up: 81 months). In the overall multivariate analysis, survival curves were better in patients with normal albumin levels than in those with hypoalbuminemia (HR=2.82; CI 95%=[1.54-5.19]; P=.001). This better prognostic value of normal albumin levels was also significant in pTNM stage ii tumors: (HR=3.76; CI 95%=[1.40-10.08]; P=.009). The 5-year mortality index was lower in patients with normal albumin levels: overall series=18.8% vs 42.9% (OR=3.24; CI 95%=[1.48-7.12]; p=0.001); pTNM stage ii=13.3% vs 44.4% (OR=5.2; CI 95%=[1.36-20.34]; P=0.004).
  
  
  CONCLUSIONS
  Pre-treatment hypoalbuminemia (<3.5g/dl) was independently related to shorter survival after tumor resection, both in the overall series of patients and in pTNM stage ii CRC. If these results are confirmed, hypoalbuminemia would be a simple and significant marker of poor prognosis, available at the initial diagnosis.
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España. Electronic address: bordafernando@yahoo.es.
authors.forename: Fernando
authors.initials: F
authors.lastname: Borda
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: Ana
authors.initials: A
authors.lastname: Borda
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: Javier
authors.initials: J
authors.lastname: Jiménez
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Zozaya
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: Carlos
authors.initials: C
authors.lastname: Prieto
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: Marta
authors.initials: M
authors.lastname: Gómez
authors.affiliation: Servicio de Digestivo, Complejo Hospitalario de Navarra, Pamplona, España.
authors.forename: Jesús
authors.initials: J
authors.lastname: Urman
authors.affiliation: NavarraBiomed, Fundación Miguel Servet (REDISSEC), Pamplona, España.
authors.forename: Berta
authors.initials: B
authors.lastname: Ibáñez
mesh_terms: D000368:Aged; D015179:Colorectal Neoplasms / Q000150:complications* / Q000401:mortality* / Q000601:surgery; D005260:Female; D006801:Humans; D034141:Hypoalbuminemia / Q000150:complications*; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
keywords: Albumin; Albúmina; Colorectal cancer; Cáncer colorrectal; Supervivencia; Survival